Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766932 | 0.85 | EPHX1 (0.52) | EPHX1PLA2G2APLA2G4AZDHHC20ZDHHC2 | |
| SCHEMBL2560023 | 0.84 | MMP1 (0.41) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL28426666 | 0.82 | MMP1 (0.40) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL21450442 | 0.81 | — | — | |
| SCHEMBL17409765 | 0.80 | MMP1 (0.39) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL5282297 | 0.78 | MMP1 (0.38) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL6858080 | 0.77 | MMP1 (0.52) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL10350313 | 0.77 | CA2 (0.37) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL7868646 | 0.77 | NPC1 (0.40) | MMP1MMP2MMP3MMP9EPHX1 | |
| SCHEMBL149370 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389752-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023131219-A1 | CONJUGATES, COMPOSITIONS AND METHODS OF USE | VIRTUOSO BINCO, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023020605-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 江苏先声药业有限公司 | 2023-02-23 | — | — | WO | disclosed |
| WO-2021225892-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) COMPRISING AN ANTI-TROP-2 ANTIBODY, COMPOSITIONS COMPRISING SUCH ADCS, AS WELL AS METHODS OF MAKING AND USING THE SAME | LEVENA (SUZHOU) BIOPHARMA CO., LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| US-20190167805-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167805-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, CD44, DNPEP | MMP1 458/4885MMP2 560/4885MMP3 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.